Dr. Buddy Creech, Pediatric Infectious Disease at Vanderbilt, talks about RSV immunizations, including eligibility criteria and challenges in finding doses. The discussion covers the importance of RSV immunizations for all age groups, the concept of pre-fusion and post-fusion in relation to the virus's fusion protein, alternatives to Bayfortas, health equity for indigenous populations, and key takeaways such as preventing lower respiratory tract disease.
New RSV vaccines target the pre-fusion form of the F protein on the virus, reducing symptom severity and hospitalizations.
RSV vaccination efforts may expand to various age groups to reduce the overall burden of disease and protect vulnerable populations.
Deep dives
RSV is a significant risk for both infants and older adults
RSV is a leading cause of medically attended respiratory tract infections in infants and older adults. The disease burden is highest in these age groups, and it is crucial to prevent RSV infections to protect both individuals and those around them.
New RSV immunizations for all ages
New immunizations have been developed for RSV in both infants and adults. Bayfortas is a passive immunization given to infants, while Pfizer and GSK vaccines are available for adults. These vaccines target the pre-fusion form of the F protein on the RSV virus, reducing the severity of symptoms and hospitalizations.
Differentiating between pediatric and adult RSV immunizations
Pediatric immunizations are focused on passive immunization with Bayfortas or active immunization with the Pfizer vaccine. Adults can receive either the Pfizer or GSK vaccine. It is important to administer the appropriate vaccine based on age and risk factors.
Future implications and impact of RSV vaccines
RSV vaccination efforts may expand to various age groups to reduce the overall burden of disease. Vaccinating pregnant women can also provide protection to newborns. Ongoing studies will further examine the potential impact on preventing reactive airways disease and asthma later in life. It is essential to prioritize vulnerable populations and work towards widespread accessibility of RSV vaccines.
The Curbsiders and Cribsiders are back with a very special Med-Peds collaboration on RSV immunizations! Dr. Buddy Creech, Pediatric Infectious Disease at Vanderbilt, walks us through these breakthrough “vaccines" for both adults and kids. He teaches us about their mechanisms of action, eligibility criteria, and why it’s been so challenging to find doses this season. Get ready for your next shot of fun!
Get the Snipd podcast app
Unlock the knowledge in podcasts with the podcast player of the future.
AI-powered podcast player
Listen to all your favourite podcasts with AI-powered features
Discover highlights
Listen to the best highlights from the podcasts you love and dive into the full episode
Save any moment
Hear something you like? Tap your headphones to save it with AI-generated key takeaways
Share & Export
Send highlights to Twitter, WhatsApp or export them to Notion, Readwise & more
AI-powered podcast player
Listen to all your favourite podcasts with AI-powered features
Discover highlights
Listen to the best highlights from the podcasts you love and dive into the full episode